Open AccessReduced plasma desmosterol‐to‐cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease
Author(s) -
Sato Yoshiaki,
Bernier Francois,
Yamanaka Yasukazu,
Aoshima Ken,
Oda Yoshiya,
Ingelsson Martin,
Lannfelt Lars,
Miyashita Akinori,
Kuwano Ryozo,
Ikeuchi Takeshi
Publication year - 2015
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1016/j.dadm.2014.11.009
Subject(s) - desmosterol , cognitive decline , disease , alzheimer's disease , dementia , psychology , cognition , cholesterol , medicine , psychiatry , sterol
Background We here examined whether plasma desmosterol‐to‐cholesterol ratio (DES/CHO) is decreased in patients with Alzheimer's disease (AD) and investigated the association between plasma DES/CHO and longitudinal cognitive decline. Methods Plasma DES/CHO of AD patients and age‐matched controls in a Japanese cross‐sectional cohort was determined. Plasma DES/CHO at baseline and follow‐up visits was assessed in relation to cognitive decline in Japanese and Swedish longitudinal cohorts. Results Plasma DES/CHO was significantly reduced in Japanese AD patients and significantly correlated with Mini‐Mental State Examination (MMSE) score. The longitudinal analysis revealed that plasma DES/CHO in AD patients shows a significant decrease at follow‐up intervals. The decline in plasma DES/CHO is larger in the AD group with rapid progression than in that with slow progression. The changes in plasma DES/CHO significantly correlated with changes in the MMSE score. Conclusion Plasma DES/CHO is decreased in AD patients and may serve as a longitudinal surrogate marker associated with cognitive decline.